Release issued 23rd July 2007

York, UK 23^rd July 2007

With the average deal value now estimated at over $900 million and in-licensed products accounting for 30% of big pharma revenue the pressure to find the right partner and do the right deal is now immense. It is imperative that such discussions are approached from a fully informed position by people with the experience to move the talks in the right direction.

Pharmalicensing now offers in-depth and involved consulting to guide you through the process of licensing. Our service provides you with all of the elements, whilst minimizing the time and costs associated with licensing. Our flexibility ensures you remain in control at all times as you progress from initial groundwork, through partner identification to negotiating and closing the deal.

The service is broken down into key elements which can be purchased individually or in combination, as and when you require it. These are:

• Analytical reports - we provide bespoke reports detailing competitive landscapes or deal benchmarking
• Partner Identification - we identify and prioritize companies for you to target
• Partner Introduction - we aid you in preparing your non-confidential dossier before approaching potential partners on your behalf to arrange meetings
• Representation and deal closure - our experts support and guide you as you move through complex negotiations through to deal closure

For more information on our consultancy services contact our team on tel: +44 1904 520460 or email: consulting@pharmalicensing.com

Pharmalicensing Ltd (pharmalicensing.com), based in York, UK, is the leading online global resource for partnering, licensing and business development within the life science and biopharmaceutical industry.

Contact: Johan Ohlsson, Strategic Analyst, Business Development (johan.ohlsson@pharmalicensing.com; Tel +44 1904 520491)

(4th January 2008) UTEK Corporation Acquires Pharmalicensing, Ltd.

(25th July 2007) Pharmalicensing launches 3rd edition of top selling licensing agreement report

(15th January 2007) New report from Pharmalicensing highlights the R&D opportunities in China

(1st December 2006) Pharmalicensing's latest report reveals new early stage dealmaking trends

(6th June 2006) Pharmalicensing re-launches reports on the top 50 biopharmaceutical companies